Vanguard Global Advisers
BMRN icon

Vanguard Global Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Vanguard Global Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.49M Buy
113,483
+16,020
+16% +$878K ﹤0.01% 718
2026
Q1 		$5.51M Buy
+97,463
New +$5.68M ﹤0.01% 739

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Global Advisers's BMRN Position: Q2 2026 in Review

Vanguard Global Advisers increased its BioMarin Pharmaceuticals (BMRN) stake by 16% in Q2 2026, buying an estimated $878K and bringing the position to 113,483 shares worth $6.49M. The position accounts for ﹤0.01% of the portfolio, ranked #718.

Vanguard Global Advisers first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 555 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Vanguard Global Advisers held 113,483 shares of BioMarin Pharmaceuticals worth $6.49M as of Q2 2026.
  • Vanguard Global Advisers bought 16,020 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $878K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #718 holding.
  • Vanguard Global Advisers first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.